Speaker:
Dr. Jessica Boyd. phd. Clinical Associate Professor at the Department of Pathology at the University of Utah School of Medicine.
Dr. Jessica Boyd is a Clinical Associate Professor at the Department of Pathology at the University of Utah School of Medicine. She is also medical director of urine toxicology and trace elements at ARUP Laboratories. She completed her PhD at the University of Alberta followed by Clinical Biochemistry Fellowship training at the University of Calgary/Calgary Laboratory Services. She is board certified by the Canadian Academy of Clinical Biochemistry and the American Board of Clinical Chemistry in Toxicological Chemistry
Overview:
The gabapentinoids, gabapentin and pregabalin, have been approved for use as anticonvulsants and in limited pain applications. However, there is increasing evidence that they are used extensively off-label for pain management and in combination with opioids. This presentation will review the history and use of gabapentin and pregabalin and outline the concerns of taking them with opioids. Analytical options for urine drug testing of gabapentin and pregabalin will also be discussed.
Objectives:
At the conclusion of this session, participants will be able to:
- Describe the current use of gabapentin and pregabalin
- Discuss the concerns and prevalence of concurrent gabapentinoid and opioid use
- Discuss analytical detection of gabapentin and pregabalin in urine